| 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (NCT05475210) | Molecular Targeting Technologies, Inc. | 2022-06-18 |
| Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (NCT05870423) | Erasmus Medical Center | 2022-06-01 |
| Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients (NCT05396118) | Rigshospitalet, Denmark | 2022-05-18 |
| Lutathera and ASTX727 in Neuroendocrine Tumours (NCT05178693) | Imperial College London | 2022-04-25 |
| Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) (NCT05237934) | National Cancer Institute (NCI) | 2022-04-25 |
| Iconographic Registry of Pancreatobiliary Endoscopy Procedures (NCT06344507) | IRCCS San Raffaele | 2022-03-28 |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (NCT05477576) | RayzeBio, Inc. | 2022-03-24 |
| Clinical Application of the Prototype J-PET Device (NCT06211803) | Jagiellonian University | 2022-03-11 |
| 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors (NCT04888481) | University of Alberta | 2022-02-15 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study (NCT05554003) | European Institute of Oncology | 2022-01-14 |
| A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors (NCT04893759) | Ascentage Pharma Group Inc. | 2022-01-06 |
| Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study (NCT05013957) | University Hospital, Basel, Switzerland | 2022-01-01 |
| Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors (NCT04672876) | University of Chicago | 2022-01-01 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study (NCT05167071) | Harbour BioMed (Guangzhou) Co. Ltd. | 2021-12-28 |
| Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (NCT04919226) | ITM Solucin GmbH | 2021-12-21 |
| Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (NCT05153772) | Orano Med LLC | 2021-12-21 |
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (NCT05053854) | Peter MacCallum Cancer Centre, Australia | 2021-12-08 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (NCT05000294) | University of Florida | 2021-12-07 |
| Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm (NCT05113355) | Peking Union Medical College Hospital | 2021-11-17 |
| Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma (NCT05076786) | Peking Union Medical College Hospital | 2021-10-27 |
| Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. (NCT06159920) | IRCCS San Raffaele | 2021-10-27 |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET (NCT04954820) | Institut du Cancer de Montpellier - Val d'Aurelle | 2021-10-18 |
| CapTemY90 for Grade 2/3 NET Liver Metastases (NCT04339036) | Abramson Cancer Center at Penn Medicine | 2021-10-07 |
| A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 (NCT05017662) | Ariceum Therapeutics GmbH | 2021-09-14 |
| Telotristat With Lutathera in Neuroendocrine Tumors (NCT04543955) | Lowell Anthony, MD | 2021-09-13 |
| Open-label Study of Surufatinib in Japanese Patients (NCT05077384) | Hutchmed | 2021-09-02 |
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (NCT04848337) | University of Michigan Rogel Cancer Center | 2021-05-25 |
| Spanish Series of Patients Treated With the Radionuclide Lutetium177 (NCT04949282) | Sociedad Española de Medicina Nuclear e Imagen Molecular | 2021-05-10 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors (NCT06015802) | Sun Yat-sen University | 2021-04-01 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT04579757) | Hutchmed | 2021-03-05 |
| Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors (NCT04804371) | University Health Network, Toronto | 2021-03-04 |
| Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NCT04713202) | Chandrikha Chandrasekhara | 2021-03-03 |
| A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) (NCT04438304) | Clarity Pharmaceuticals Ltd | 2021-03-02 |
| A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 (NCT04524208) | Karsten Gavenis | 2021-03-01 |
| Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors (NCT04831567) | AC Camargo Cancer Center | 2021-02-04 |
| 18F-DOPA II - PET Imaging Optimization (NCT04706910) | University of Alberta | 2021-01-20 |
| 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours (NCT06155994) | Medical University Innsbruck | 2021-01-20 |
| Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (NCT04696042) | Asan Medical Center | 2021-01-01 |
| Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors (NCT04897542) | First Affiliated Hospital of Fujian Medical University | 2020-12-01 |
| Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s (NCT04488263) | National Cancer Institute (NCI) | 2020-11-24 |
| Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT (NCT04622631) | Dr. Nayruz Knaana | 2020-11-01 |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (NCT04291885) | Melanoma and Skin Cancer Trials Limited | 2020-10-26 |
| Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors (NCT04510311) | University of Michigan Rogel Cancer Center | 2020-10-19 |
| Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors (NCT04552847) | Universitaire Ziekenhuizen KU Leuven | 2020-10-07 |
| Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain (NCT04034745) | Andrew Hendifar, MD | 2020-10-01 |
| Impact of Peptides and Chelators on Somatostatin Receptor Antagonists (NCT04491851) | Peking Union Medical College Hospital | 2020-10-01 |
| Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (NCT04584008) | Peking University | 2020-09-23 |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (NCT04464122) | University of Roma La Sapienza | 2020-09-14 |
| Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver (NCT04544098) | Memorial Sloan Kettering Cancer Center | 2020-09-02 |
| Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment (NCT05334290) | Massimo Falconi | 2020-08-06 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents (NCT03923257) | Sue O'Dorisio | 2020-08-04 |
| Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors (NCT04365023) | Assistance Publique - Hôpitaux de Paris | 2020-07-02 |
| Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor (NCT06540937) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-07-01 |
| Nutrition in Gastrointestinal Tumors (NCT04476082) | University Medicine Greifswald | 2020-06-25 |
| Registry on NEN Patients and COVID-19 (NCT04444401) | European Institute of Oncology | 2020-06-15 |
| 18F-AmBF3-TATE PET/CT for Imaging NET Patients (NCT04207762) | British Columbia Cancer Agency | 2020-06-09 |
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors (NCT04074135) | National Cancer Institute (NCI) | 2020-06-02 |
| Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors (NCT05168631) | Latin American Cooperative Oncology Group | 2020-05-16 |
| Portal Vein Resection in Pancreatic Neuroendocrine Tumours (NCT04336839) | Royal Free Hospital NHS Foundation Trust | 2020-05-01 |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (NCT04375267) | Vastra Gotaland Region | 2020-04-23 |
| Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET (NCT04385992) | IRCCS San Raffaele | 2020-03-09 |
| A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use (NCT03145857) | AHS Cancer Control Alberta | 2020-03-05 |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (NCT04276597) | Excel Diagnostics and Nuclear Oncology Center | 2020-03-04 |
| Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities (NCT04152928) | Tel-Aviv Sourasky Medical Center | 2020-02-25 |
| 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors (NCT04258592) | Universitaire Ziekenhuizen KU Leuven | 2020-02-07 |
| A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. (NCT04166006) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2019-12-12 |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers (NCT03935893) | Udai Kammula | 2019-12-03 |
| Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors (NCT04318561) | Peking Union Medical College Hospital | 2019-12-01 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department (NCT04104529) | Institut du Cancer de Montpellier - Val d'Aurelle | 2019-10-28 |
| Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. (NCT03980925) | Grupo Espanol de Tumores Neuroendocrinos | 2019-10-11 |
| SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors (NCT02840149) | Jewish General Hospital | 2019-10-01 |
| Cryoablation of Bone Metastases From Endocrine Tumors (NCT03986593) | Instituto do Cancer do Estado de São Paulo | 2019-09-26 |
| Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers (NCT04077372) | Stanford University | 2019-09-16 |
| Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms (NCT03834701) | Catholic University of the Sacred Heart | 2019-09-01 |
| Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment (NCT04066322) | Fudan University | 2019-08-25 |
| Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice (NCT03895463) | Ipsen | 2019-08-01 |
| Image-Enhanced Endoscopy in the Gastrointestinal Tract (NCT04085211) | King's College Hospital NHS Trust | 2019-07-01 |
| PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment (NCT04331912) | University of Warmia and Mazury | 2019-07-01 |
| A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) (NCT05268952) | University Hospital, Antwerp | 2019-05-27 |
| Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia (NCT04045834) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-05-05 |
| Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors (NCT03883776) | Universitaire Ziekenhuizen KU Leuven | 2019-04-11 |
| 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors (NCT03873870) | University Health Network, Toronto | 2019-03-28 |
| Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (NCT03870399) | AC Camargo Cancer Center | 2019-03-13 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (NCT03910660) | BioXcel Therapeutics Inc | 2019-02-12 |
| TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (NCT04362436) | Imperial College London | 2019-02-05 |
| The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET (NCT03840720) | Vastra Gotaland Region | 2019-02-01 |
| Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer (NCT04194125) | University of Warmia and Mazury | 2019-02-01 |
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361) | Dwight Owen | 2018-12-31 |
| Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors (NCT03600233) | TaiRx, Inc. | 2018-12-15 |
| Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs (NCT03722511) | Lowell Anthony, MD | 2018-12-06 |
| Neuroendocrine Tumors of Old Patients in the West of France (NCT03749681) | University Hospital, Brest | 2018-12-01 |
| Post-Authorization Long-Term Safety Study of LUTATHERA (NCT03691064) | Advanced Accelerator Applications | 2018-11-28 |
| A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System (NCT03670030) | Robert Ramirez | 2018-11-05 |
| MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents (NCT03217097) | Hospices Civils de Lyon | 2018-10-16 |
| Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases (NCT03724409) | Sandeep Laroia | 2018-10-11 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |